CGON
CG Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$73.40
−1.70%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.86
- Revenue estimate
- $547.7K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.90
- EPS estimate
- -$0.66
- Revenue actual
- $1.2M
- Revenue estimate
- $360.8K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -17.5%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $83
- PT range
- $79 – $85
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.66 | -$0.90 | Miss -35.51% | $1.2M |
| May 8, 2026 | -$0.58 | -$0.71 | Miss -22.41% | $1.1M |
| Nov 14, 2025 | -$0.56 | -$0.57 | Miss -1.96% | $1.7M |
| Aug 8, 2025 | -$0.49 | -$0.54 | Miss -10.20% | — |
| Mar 28, 2025 | -$0.41 | -$0.48 | Miss -17.07% | $456.0K |
| Aug 8, 2024 | -$0.42 | -$0.28 | Beat 33.33% | $111.0K |
| May 9, 2024 | -$0.35 | -$0.36 | Miss -2.86% | $529.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026